Compare SM & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SM | BIO |
|---|---|---|
| Founded | 1908 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.0B |
| IPO Year | 1996 | N/A |
| Metric | SM | BIO |
|---|---|---|
| Price | $31.18 | $304.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $34.36 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 3.8M | 281.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,154,000,000.00 | N/A |
| Revenue This Year | $129.01 | $2.74 |
| Revenue Next Year | $6.29 | $3.20 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | ★ 17.24 | N/A |
| 52 Week Low | $17.45 | $236.73 |
| 52 Week High | $35.88 | $343.12 |
| Indicator | SM | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 59.55 |
| Support Level | $30.06 | $291.87 |
| Resistance Level | $31.50 | $310.67 |
| Average True Range (ATR) | 0.98 | 7.91 |
| MACD | 0.56 | 0.84 |
| Stochastic Oscillator | 97.07 | 97.36 |
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.